Advertisement

Head and Neck Pathology

, Volume 12, Issue 2, pp 237–243 | Cite as

Diagnostic Approaches for Salivary Gland Tumors with Secretory and Microcystic Features

  • Ha Young Woo
  • Eun Chang Choi
  • Sun Och YoonEmail author
Original Paper

Abstract

Secretory carcinoma (SC) of the salivary gland is a new entity that shares the unique morphologic features and cytogenetic characteristics of the ETV6-NTRK3 fusion gene with its breast counterpart. Before identification of SC of the salivary gland, it was most frequently diagnosed as acinic cell carcinoma (AciCC). We retrospectively reviewed our own database of salivary gland tumors harboring microcystic and papillary architecture and/or secretory features that were originally diagnosed as AciCC. We selected nine cases of AciCC showing diffuse S-100 expression on immunohistochemistry (IHC). A recently diagnosed case of SC was included in the study as a reference sample. We performed IHC of S-100 and mammaglobin and ETV6 gene fluorescence in situ hybridization (FISH) in all cases. Seven cases were positive for both S-100 and mammaglobin, while five of the seven (71.4%) demonstrated ETV6 gene translocation by FISH. In the cases which did not co-express either S-100 or mammaglobin on IHC, ETV6 gene rearrangement was not shown on FISH. In conclusion, if a salivary gland tumor has morphologic features of SC with co-expression of S-100 and mammaglobin, ETV6 FISH can be performed to confirm the diagnosis of SC of the salivary gland.

Keywords

Secretory carcinoma Salivary gland tumor S-100 Mammaglobin ETV6-NTRK3 

Notes

Acknowledgements

The study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2015R1D1A1A09059399).

Compliance with Ethical Standards

Conflict of interest

The authors have no conflicts of interest or funding to disclose.

Research Involving Human and Animal Rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

12105_2017_864_MOESM1_ESM.tif (12.6 mb)
Representative images of DOG1 immunohistochemical staining. A) Showed negative expression of DOG1 (case 6); B) Showed diffuse cytoplasmic expression of DOG1 (case 5). (TIF 12912 KB)

References

  1. 1.
    Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608.PubMedGoogle Scholar
  2. 2.
    Tavassoli FA, Norris HJ. Secretory carcinoma of the breast. Cancer. 1980;45:2404–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012;61:387–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Chiosea SI, Griffith C, Assaad A, Seethala RR. The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma. Am J Surg Pathol. 2012;36:343–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Connor A, Perez-Ordonez B, Shago M, Skalova A, Weinreb I. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012;36:27–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Fehr A, Loning T, Stenman G. Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion. Am J Surg Pathol. 2011;35:1600–2.CrossRefPubMedGoogle Scholar
  7. 7.
    Lei Y, Chiosea SI. Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. Head Neck Pathol. 2012;6:166 – 70.CrossRefPubMedGoogle Scholar
  8. 8.
    Pinto A, Nose V, Rojas C, Fan YS, Gomez-Fernandez C. Searching for mammary analogue [corrected] secretory carcinoma of salivary gland among its mimics. Mod Pathol. 2014;27:30 – 7.CrossRefPubMedGoogle Scholar
  9. 9.
    Bishop JA, Yonescu R, Batista D, Begum S, Eisele DW, Westra WH. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. Hum Pathol. 2013;44:1982–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Li W, Lee MR, Choi E, Cho MY. Clinicopathologic significance of survivin expression in relation to CD133 expression in surgically resected stage II or III colorectal cancer. J Pathol Transl Med. 2017;51:17–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Bishop JA, Yonescu R, Batista D, Eisele DW, Westra WH. Most nonparotid “acinic cell carcinomas” represent mammary analog secretory carcinomas. Am J Surg Pathol. 2013;37:1053–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bishop JA, Yonescu R, Batista DA, Westra WH, Ali SZ. Cytopathologic features of mammary analogue secretory carcinoma. Cancer Cytopathol. 2013;121:228–33.CrossRefPubMedGoogle Scholar
  13. 13.
    Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24:937–46.CrossRefPubMedGoogle Scholar
  15. 15.
    Skalova A. Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol. 2013;7(Suppl 1):S30–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum Pathol. 2015;46:94–103.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang L, Liu Y, Lin X, Zhang D, Li Q, Qiu X, et al. Low-grade cribriform cystadenocarcinoma of salivary glands: report of two cases and review of the literature. Diagn Pathol. 2013;8:28.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013;7:35–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Shah AA, Wenig BM, LeGallo RD, Mills SE, Stelow EB. Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma. Head Neck Pathol. 2015;9:85–95.CrossRefPubMedGoogle Scholar
  20. 20.
    Said-Al-Naief N, Carlos R, Vance GH, Miller C, Edwards PC. Combined DOG1 and mammaglobin immunohistochemistry is comparable to ETV6-breakapart analysis for differentiating between papillary cystic variants of acinic cell carcinoma and mammary analogue secretory carcinoma. Int J Surg Pathol. 2017;25:127–40.CrossRefPubMedGoogle Scholar
  21. 21.
    Chenevert J, Duvvuri U, Chiosea S, Dacic S, Cieply K, Kim J, et al. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012;25:919–29.CrossRefPubMedGoogle Scholar
  22. 22.
    Hemminger J, Iwenofu OH. Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms. Histopathology. 2012;61:170–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of PathologyYonsei University College of MedicineSeoulRepublic of Korea
  2. 2.Department of OtorhinolaryngologyYonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations